Validation of dried blood sampling for infliximab in IBD-patients

Validation of dried blood sampling for infliximab in IBD-patients - Dried blood sampling infliximab

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON43041

Enrollment

Registered

2016-10-19

Start date

2017-01-10

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory Bowel Disease

Interventions

Dried Blood Spot

Infliximab

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: - Age from 18 years, either male or female - Diagnosis of IBD - Receiving infliximab therapy

Exclusion criteria

Exclusion criteria: - Contra-indication to infliximab (TBC, severe infections or congestive heart failure)

Design outcomes

Primary

Measure	Time frame
Primary: to investigate feasibility of DBS from finger prick for measuring infliximab drug levels and ATIs compared with the results of venepuncture serum sample measurements.	—

Secondary

Measure	Time frame
To compare levels of albumin and CRP from DBS with the results of venepuncture serum sample measurement and to investigate feasibility of DBS from finger prick at home.	—

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)